April 28, 2017
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

MCL is a rare form of non-Hodgkin lymphoma and represents about 6 "...




Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Dacogen (decitabine injection) and for I month afterwards, and to use effective contraception during this time, [See WARNINGS AND PRECAUTIONS].

Men should be advised not to father a child while receiving treatment with Dacogen (decitabine injection) , and for 2 months afterwards. During these times, men with female partners of childbearing potential should use effective contraception [See WARNINGS AND PRECAUTIONS and Nonclinical Toxicology].

Patients should be advised to monitor and report any symptoms of neutropenia, thrombocytopenia, or fever to their physician as soon as possible [See WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 4/1/2010
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.

Health Resources
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations